Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Kroger Co (KR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Kroger Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Kroger Co trades at $60.73 (market cap $37.09B). The key difference: Alnylam Pharmaceuticals, Inc. and Kroger Co are close in size by market cap, and Kroger Co pays a 2.38% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | KR | |
|---|---|---|
Market Cap | $39.89B | $37.09B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $75.60 |
52-Week Low | $278.09 | $55.53 |
Enterprise Value | $38.15B | $57.18B |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Kroger (KR) trades at $60.54, up 1.14% today, near the analyst consensus price target of $68.63. The stock shows bullish technical signals despite a mixed earnings history, with recent beats in Q3 and Q4 2025 but a miss in Q1 2026. Fundamentals reveal a low P/S ratio of 0.26 and steady dividends, while the recent $1.65 billion acquisition of Giant Eagle aims to expand Midwest presence amid intense grocery competition.
KR offers value with solid cash flow and growth initiatives, but risks include margin pressure from industry competition and integration challenges from acquisitions. Analyst sentiment is positive with 48% buy ratings, supporting a cautious bullish outlook for patient investors focused on long-term retail consolidation benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
